Saturday, December 16, 2023 1:14:34 PM
Poor Man-,
You should know by now that no one values this platform based on its potential but rather on current status. No true long with any vision at all is going to sell based on current status to those who will only value it as that because of the real big threat it represents to many others if it gets away from their control.
Patience is what brings the reward from this platform because any offer that might have ever been made before from big pharma was done under the assumption that NWBO could not or would not finish. They were wrong and now they must value the platform at the rate of NWBO’s potential gain and their potential loss from not being involved. They are in no hurry to do that unless there is an agreement in concept in place and that will definitely depend on Edens and scale up potential. Dilution has just been part of the path investors have been forced to follow because big pharma chose to under value the potential to realize the greater gains from recognition of true platform value over time. Linda and true longs have not made that mistake. Tic toc; ). Best wishes.
You should know by now that no one values this platform based on its potential but rather on current status. No true long with any vision at all is going to sell based on current status to those who will only value it as that because of the real big threat it represents to many others if it gets away from their control.
Patience is what brings the reward from this platform because any offer that might have ever been made before from big pharma was done under the assumption that NWBO could not or would not finish. They were wrong and now they must value the platform at the rate of NWBO’s potential gain and their potential loss from not being involved. They are in no hurry to do that unless there is an agreement in concept in place and that will definitely depend on Edens and scale up potential. Dilution has just been part of the path investors have been forced to follow because big pharma chose to under value the potential to realize the greater gains from recognition of true platform value over time. Linda and true longs have not made that mistake. Tic toc; ). Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
